➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKesson
Medtronic
Moodys
McKinsey

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,025,635


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,025,635
Title:Device and methods for treating paranasal sinus conditions
Abstract: Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.
Inventor(s): Eaton; Donald J. (Woodside, CA), Tice; Thomas R. (Indian Springs, AL), Downie; David B. (Cupertino, CA), Arensdorf; Patrick A. (Palo Alto, CA), Brenneman; Rodney (San Juan Capistrano, CA), Biggs; Danielle L. (Hoover, AL)
Assignee: Intersect ENT, Inc. (Palo Alto, CA)
Application Number:11/398,342
Patent Claims: 1. A system for treating a paranasal sinus condition comprising: a) an introducer; and b) a fully implantable, bioabsorable, paranasal sinus device comprising a first member and a plurality of prongs, each prong having a proximal end extending from a distal end of the first member and a free distal end, wherein the first member and plurality of prongs are made of a bioabsorbable polymer, and an active agent configured to release therefrom; wherein the device has a first configuration wherein the plurality of prongs is collapsed to permit the device to pass through a sinus ostium or surgically created fenestration and a second expanded configuration after placement into a sinus cavity.

2. The system of claim 1 wherein the introducer comprises a conduit having a lumen and a distal portion, and wherein the paranasal sinus device is placed within the lumen or is releasably secured to the distal portion of the introducer.

3. The system of claim 2 further comprising a sheath.

4. The system of claim 3 wherein the paranasal sinus device is delivered into the sinus cavity by retracting the sheath to deploy the first member and expand the plurality of prongs.

5. The system of claim 2 wherein the introducer is preloaded with the paranasal sinus device.

6. The system of claim 1 wherein the paranasal sinus condition is sinus inflammation due to functional endoscopic sinus surgery (FESS).

7. A method for treating a paranasal sinus condition comprising: fully implanting a paranasal sinus device within a patient, wherein the paranasal sinus device comprises a first member and a plurality of prongs, each prong having a proximal end extending from a distal end of the first member and a free distal end, wherein the first member and plurality of prongs are made of a bioabsorbable polymer, and an active agent configured to release therefrom; wherein the plurality of prongs expand to contact surrounding tissue in the paranasal sinus when the device is fully implanted.

8. The method of claim 7 wherein the paranasal sinus device releases the active agent to treat the paranasal sinus condition for about one week.

9. The method of claim 7 wherein the paranasal sinus device releases the active agent to treat the paranasal sinus condition for about two weeks.

10. The method of claim 7 wherein the paranasal sinus device releases the active agent to treat the paranasal sinus condition for about three weeks.

11. The method of claim 7 wherein the paranasal sinus device releases the active agent to treat the paranasal sinus condition for about one month.

12. The system of claim 2 wherein the paranasal sinus device is delivered into the sinus cavity by advancing a pusher through the conduit lumen.

13. The system of claim 1 wherein the paranasal sinus device is releasably secured to the introducer.

14. The system of claim 1 wherein the introducer is malleable.

15. The system of claim 1 wherein the paranasal sinus condition is sinus inflammation.

16. The method of claim 7 wherein the active agent is included in a coating on the device.

17. The method of claim 16 wherein the plurality of prongs comprises one or more anchoring elements.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Boehringer Ingelheim
McKinsey
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.